TGA / PMDA / NMPA · Asia-Pacific
hema- — TGA / PMDA / NMPA regulatory status
hema- regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 211 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 230LE301 | Phase 3 | Biogen | 2023-505634-94-00 |
| 230LE303 | Phase 3 | Biogen | 2023-505695-30-00 |
| 230LE304 | Phase 3 | Biogen | 2023-505696-74-00 |
| 230LE306 | Phase 3 | Biogen | 2023-505635-13-00 |
| 80202135SLE3001 | Phase 3 | Janssen-Cilag International N.V | 2025-523552-31-00 |
| ALXN1210-TMA-313 | Phase 3 | Alexion Europe SAS | 2023-510107-22-00 |
| APHP200073 | Phase 3 | PARItec | 2024-516018-39-00 |
| APHP240920 | Phase 3 | PARItec | 2024-520089-70-00 |
| ATLG | Phase 3 | Chinese Academy of | NCT06525519 |
| Anifrolumab | Phase 3 | AstraZeneca | NCT06015737 |
| Anifrolumab | Phase 3 | AstraZeneca | 2024-513031-24-00 |
| Anifrolumab | Phase 3 | AstraZeneca | NCT02446912, NCT02794285 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12281327 | Lymphohematopoietic engineering using CAS9 base editors | US |
| 12059437 | Methods and compositions for hematopoietic stem cell mobilization | US |
| 11944627 | Methods for treating hematological malignancies and Ewing's sarcoma | US |
| 11642379 | Hematopoietic stem cell engraftment | US |
| 11559565 | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides | US |
| 11419875 | Compounds and compositions for treating hematological disorders | US |
| 11312953 | Compositions and methods of nucleic acid-targeting nucleic acids | US |
| 11110092 | Methods of treating hematologic cancers | US |
| 11052066 | Ultrapure tetrahydrocannabinol-11-oic acids | US |
| 10822299 | Compounds and methods for hematopoietic regeneration | US |
| 10369131 | Ultrapure tetrahydrocannabinol-11-oic acids | US |
| 10154986 | Ultrapure tetrahydrocannabinol-11-oic acids | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of hema-?
hema- currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get hema- regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to hema-?
This spoke lists 211 published programs associated with hema- in our pipeline index.